Michael Kaleko

4.7k citations

76 papers · 3.9k indexed · h-index 37

Molecular Biology top 2%
Genetics top 0.5%
Oncology top 2%
Infectious Diseases top 5%
Endocrinology, Diabetes and Metabolism top 2%

Co-authors: A. Dusty Miller Sheila Connelly Alan McClelland William J. Rutter Theodore A Smith Dawn B. Kayda Michele G. Mehaffey Neeraja Idamakanti
Topics: Virus-based gene therapy research (37 papers)Hemophilia Treatment and Research (14 papers)Clostridium difficile and Clostridium perfringens research (12 papers)
Cited by: Genetics Oncology Molecular Biology
Journals: Cell Journal of Biological Chemistry Nature Genetics
Partner nations: United States Switzerland South Africa

In The Last Decade

Michael Kaleko

75 papers receiving 3.8k citations

Peers

Countries citing papers authored by Michael Kaleko

Since Specialization

Citations

This map shows the geographic impact of Michael Kaleko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Kaleko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Kaleko more than expected).

Fields of papers citing papers by Michael Kaleko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Kaleko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Kaleko. The network helps show where Michael Kaleko may publish in the future.

Co-authorship network of co-authors of Michael Kaleko

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Kaleko. A scholar is included among the top collaborators of Michael Kaleko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Kaleko. Michael Kaleko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	2216MO VIRAGE trial: Randomized phase IIb, open-label, study of nab-paclitaxel and gemcitabine with/without intravenous VCN-01 in patients with metastatic pancreatic cancer (mPDAC) 2025 ·Annals of Oncology ·(unknown),Roberto Pazo-Cid,T. Macarulla Mercadé,Berta Laquente,(unknown),(unknown),Andrés J. Muñoz Martín,(unknown),(unknown),Tara Elisabeth Seery,(unknown),Chris Nevala-Plagemann,Vivek Sharma,Eva Martínez de Castro,C. Le,Michael Kaleko,(unknown),C. Blasco,(unknown),Manuel Hidalgo	0
2	VIRAGE: A phase IIb, open-label, randomized study of nab-paclitaxel and gemcitabine plus/minus VCN-01 in patients with metastatic pancreatic cancer. 2024 ·Journal of Clinical Oncology ·Rocio García‐Carbonero,Roberto Pazo-Cid,Teresa Macarulla,(unknown),Edward Kim,Berta Laquente,Tara Elisabeth Seery,(unknown),Carmen Guillén‐Ponce,Eva Martínez de Castro,(unknown),Andrés J. Muñoz Martín,(unknown),Ignacio Garrido‐Laguna,(unknown),Michael Kaleko,(unknown),C. Blasco,Manel Cascalló,Manuel Hidalgo	1
3	Low dose oral beta-lactamase protects the gut microbiome from oral beta-lactam-mediated damage in dogs 2019 ·AIMS Public Health ·Sheila Connelly,Brian Fanelli,Nur A. Hasan,Rita R. Colwell,Michael Kaleko	6
4	620. Oral β-Lactamase Therapies Prevent Microbiome Damage and Attenuate Antibiotic Resistance From IV and Oral Antibiotics in Large Animal Models of Antibiotic-Mediated Gut Dysbiosis 2018 ·Open Forum Infectious Diseases ·Sheila Connelly,Christian Furlan-Freguia,Brian Fanelli,Nur A. Hasan,Rita R. Colwell,Michael Kaleko	2
5	Distinct consequences of amoxicillin and ertapenem exposure in the porcine gut microbiome 2018 ·Anaerobe ·Sheila Connelly,Poorani Subramanian,Nur A. Hasan,Rita R. Colwell,Michael Kaleko	31
6	Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection 2016 ·Anaerobe ·Michael Kaleko,J. Andrew Bristol,(unknown),Todd B. Parsley,Giovanni Widmer,Saul Tzipori,Poorani Subramanian,Nur A. Hasan,(unknown),John F. Kokai‐Kun,Joseph Sliman,Annie Jones,Sheila Connelly	55
7	Angiopoietin‐2 enhances retinal vessel sensitivity to vascular endothelial growth factor 2004 ·Journal of Cellular Physiology ·Yuji Oshima,Tye Deering,Sachiko M. Oshima,Hiroyuki Nambu,P. Seshidhar Reddy,Michael Kaleko,Sheila Connelly,Sean F. Hackett,Peter A. Campochiaro	77
8	Intraocular gutless adenoviral‐vectored VEGF stimulates anterior segment but not retinal neovascularization 2004 ·Journal of Cellular Physiology ·Yuji Oshima,Kyoichi Takahashi,Sachiko M. Oshima,Yoshitsugu Saishin,Yumiko Saishin,(unknown),(unknown),P. Seshidhar Reddy,Shanthi Ganesh,Terrence W. Brann,Gene Liau,Michael Kaleko,Sheila Connelly,Peter A. Campochiaro	14
9	Potentiation of oncolytic adenoviral vector efficacy with gutless vectors encoding GMCSF or TRAIL 2004 ·Cancer Gene Therapy ·Kevin D. Burroughs,Dawn B. Kayda,Kiran Sakhuja,(unknown),John Jakubczak,J. Andrew Bristol,David L. Ennist,Paul L. Hallenbeck,Michael Kaleko,Sheila Connelly	8
10	Development of adenovirus serotype 35 as a gene transfer vector 2003 ·Virology ·P. Seshidhar Reddy,Shanthi Ganesh,(unknown),Terrence W. Brann,(unknown),Michele Kaloss,Michael Kaleko,Sheila Connelly	108
11	Mapping of the Bovine Immunodeficiency Virus Packaging Signal and RRE and Incorporation into a Minimal Gene Transfer Vector 2002 ·Virology ·(unknown),(unknown),(unknown),Jingli Zhang,Michael Kaleko,Tianci Luo	9
12	Sustained Human Factor VIII Expression in Hemophilia A Mice Following Systemic Delivery of a Gutless Adenoviral Vector 2002 ·Molecular Therapy ·P. Seshidhar Reddy,Kiran Sakhuja,Shanthi Ganesh,Lijuan Yang,Dawn B. Kayda,Terrence W. Brann,Scott Pattison,(unknown),Neeraja Idamakanti,(unknown),Michele Kaloss,Catherine Barjot,Jeffrey S. Chamberlain,Michael Kaleko,Sheila Connelly	89
13	In Vivo Dose Threshold Effect of Adenovirus-Mediated Factor VIII Gene Therapy in Hemophiliac Mice 2000 ·Molecular Therapy ·J. Andrew Bristol,Pamela S. Shirley,Neeraja Idamakanti,Michael Kaleko,Sheila Connelly	37
14	In Vivo Evaluation of an Adenoviral Vector Encoding Canine Factor VIII: High-Level, Sustained Expression in Hemophiliac Mice 1999 ·Human Gene Therapy ·(unknown),Pamela S. Shirley,J. Andrews,Dawn B. Kayda,(unknown),Michele Kaloss,(unknown),Cheryl Cameron,Colleen Notley,Christine Hough,David Lillicrap,Michael Kaleko,Sheila Connelly	36
15	An Improved Method for Generating Retroviral Producer Clones for Vectors Lacking a Selectable Marker Gene 1998 ·Blood Cells Molecules and Diseases ·Derek A. Persons,Michele G. Mehaffey,Michael Kaleko,Arthur W. Nienhuis,Elio F. Vanin	74
16	High-Level Tissue-Specific Expression of Functional Human Factor VIII in Mice 1996 ·Human Gene Therapy ·Sheila Connelly,(unknown),Alan McClelland,Michael Kaleko	57
17	Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice 1993 ·Nature Genetics ·Theodore A Smith,Michele G. Mehaffey,Dawn B. Kayda,(unknown),Soonpin Yei,Bruce C. Trapnell,Alan McClelland,Michael Kaleko	295
18	Ligand‐dependent inhibition of myoblast differentiation by overexpression of the type‐1 insulin‐like growth factor receptor 1993 ·Journal of Cellular Physiology ·LeBris S. Quinn,(unknown),(unknown),Michael Kaleko	19
19	Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. 1992 ·PubMed ·(unknown),Michael Kaleko,A. Dusty Miller,Dennis J. Slamon	138
20	Long-Term Expression of Human Adenosine Deaminase in Mice after Transplantation of Bone Marrow Infected with Amphotropic Retroviral Vectors 1990 ·Human Gene Therapy ·William Osborne,Randy A. Hock,Michael Kaleko,A. Dusty Miller	54

About Michael Kaleko

Michael Kaleko is a scholar working on Molecular Medicine, Hematology and Genetics, having authored 76 papers that have together received 3.9k indexed citations. Recurring topics across this work include Virus-based gene therapy research (37 papers), Hemophilia Treatment and Research (14 papers) and Clostridium difficile and Clostridium perfringens research (12 papers). The work is most often cited by research in Genetics (2.1k citations), Oncology (1.1k citations) and Molecular Biology (2.6k citations). Michael Kaleko has collaborated with scholars based in United States, Switzerland and South Africa. Frequent co-authors include A. Dusty Miller, Sheila Connelly, Alan McClelland, William J. Rutter, Theodore A Smith, Dawn B. Kayda, Michele G. Mehaffey, Neeraja Idamakanti, J. Victor Garcia and Bruce C. Trapnell. Their work appears in journals such as Cell, Journal of Biological Chemistry and Nature Genetics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact